Biologic therapy in primary systemic vasculitis of the young

Rheumatology

Volumn 48, Issue 8, 2009, Pages 978-986

  Eleftheriou, Despina ^a   Melo, Marianna ^a   Marks, Stephen D ^a   Tullus, Kjell ^a   Sills, John ^b   Cleary, Gavin ^b   Dolezalova, Pavla ^c   Ozen, Seza ^d   Pilkington, Clarissa ^a   Woo, Pat ^a   Klein, Nigel ^a   Dillon, Michael J ^a   Brogan, Paul A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

^c CHARLES UNIVERSITY   (Czech Republic)

^d HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Biologic therapies; Birmingham Vasculitis Activity Score; Children; Infection rate; Primary systemic vasculitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; COLCHICINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DAPSONE; ETANERCEPT; IMMUNOGLOBULIN; INFLIXIMAB; MESALAZINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; THALIDOMIDE; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADJUVANT THERAPY; ADOLESCENT; ARTICLE; BEHCET DISEASE; BIRMINGHAM VASCULITIS ACTIVITY SCORE; BRAIN ABSCESS; CHILD; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HERPES ZOSTER; HUMAN; INFECTION RATE; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INTESTINE PERFORATION; LYMPHOCYTE DEPLETION; MALE; MICROSCOPIC POLYANGIITIS; MORTALITY; ONYCHOMYCOSIS; PARONYCHIA; PLASMAPHERESIS; PNEUMONIA; POLYARTERITIS NODOSA; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; REMISSION; SCORING SYSTEM; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS INFECTION; SYSTEMIC VASCULITIS; URINARY TRACT INFECTION; WEGENER GRANULOMATOSIS; CLASSIFICATION; INFANT; NONPARAMETRIC TEST; PRESCHOOL CHILD; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VASCULITIS;

ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; VASCULITIS;

EID: 70149086501     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep148     Document Type: Article

References (43)

1. Brogan PA, Dillon MJ. Vasculitis from the pediatric perspective. Curr Rheumatol Rep 2000;2:411-16.
2. Ozen S, Anton J, Arisoy N et al. Juvenile polyarteritis: results of a multicenter survey of 110 children. J Pediatr 2004;145:517-22.
3. Akikusa JD, Schneider R, Harvey EA et al. Clinical features and outcome of pediatric Wegener's granulomatosis. Arthritis Rheum 2007;57:837-44.
4. Dillon MJ. Vasculitis treatment - new therapeutic approaches. Eur J Pediatr 2006;165:351-7.
5. Langford CA. Small-vessel vasculitis: therapeutic management. Curr Rheumatol Rep 2007;9:328-35.
6. Wright E, Dillon MJ, Tullus K. Childhood vasculitis and plasma exchange. Eur J Pediatr 2007;166:145-51.
7. Brogan PA, Dillon MJ. The use of immunosuppressive and cytotoxic drugs in non-malignant disease. Arch Dis Child 2000;83:259-64.
8. Jayne D. How to induce remission in primary systemic vasculitis. Best Pract Res Clin Rheumatol 2005;19:293-305.
9. Jayne D. Novel therapeutic approaches in vasculitis treatment. Pediatr Nephrol 2004;19:C50.
10. Pavone L, Grasselli C, Chierici E. et al. Outcome and prognostic factors during the course of primary small-vessel vasculitides. J Rheumatol 2006;33:1299-306.
11. Langford CA, Talar-Williams C, Barron KS, Sneller MC. Use of a cyclophosphamideinduction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 2003;114:463-9.
12. Haubitz M, Koch KM, Brunkhorst R. Survival and vasculitis activity in patients with end-stage renal disease due to Wegener's granulomatosis. Nephrol Dial Transplant 1998;13:1713-18.
13. Lovell DJ, Reiff A, Ilowite NT et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008;58:1496-504.
14. Marks SD, Patey S, Brogan PA et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 2005;52:3168-74.
15. Feinstein J, Arroyo R. Successful treatment of childhood onset refractory polyarteritis nodosa with tumor necrosis factor alpha blockade. J Clin Rheumatol 2005;11:219-22.
16. Wilkinson NM, Erendzhinova E, Zeft A, Cabral DA. Infliximab as rescue therapy in three cases of paediatric Wegener's granulomatosis. Rheumatology (Oxford) 2006;45:1047-8.
17. El-Hallak M, Binstadt BA, Leichtner AM et al. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases. J Pediatr 2007;150:376-82.
18. Jennette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37: 187-92.
19. Fries JF, Hunder GG, Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis Rheum 1990;33:1135-6.
20. Ozen S, Ruperto N, Dillon MJ et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis 2006;65:936-41.
21. Luqmani RA, Bacon PA, Moots RJ et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. Q J Med 1994;87:671-8.
22. Jayne D, Rasmussen N, Andrassy K et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44.
23. de GK, Rasmussen N, Bacon PA et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:2461-9.
24. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005;352: 351-61.
25. Brogan PA, Shah V, Brachet C et al. Endothelial and platelet microparticles in vasculitis of the young. Arthritis Rheum 2004;50:927-36.
26. Hellmich B, Flossmann O, Gross WL et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007;66:605-17.
27. Erdbruegger U, Grossheim M, Hertel B et al. Diagnostic role of endothelial microparticles in vasculitis. Rheumatology (Oxford) 2008;47:1820-5.
28. Clarke LA, Shah V, Melo M et al. Circulating endothelial cells and endothelial progenitor cells in primary systemic vasculitis. Clin Exp Rheumatol 2006;25:86-7.
29. Booth A, Harper L, Hammad T et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004;15:717-21.
30. Bartolucci P, Ramanoelina J, Cohen P et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 2002;41:1126-32.
31. Lamprecht P, Voswinkel J, Lilienthal T et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 2002;41:1303-7.
32. Booth AD, Jayne DR, Kharbanda RK et al. Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation 2004;109:1718-23.
33. Burns JC, Mason WH, Hauger SB et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 2005;146:662-7.
34. van Laar JA, Missotten T, van Daele PL, Jamnitski A, Baarsma GS, van Hagen PM. Adalimumab: a new modality for Behcet's disease? Ann Rheum Dis 2007;66:565-6.
35. Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 2005;257:540-8.
36. Aries PM, Hellmich B, Voswinkel J et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006;6:853-8.
37. Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 2006;54:2970-82.
38. Stasi R, Stipa E, Del PG, Amadori S, Newland AC, Provan D. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) 2006;45:1432-6.
39. Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006;173:180-7.
40. Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibodyassociated vasculitis. Arthritis Rheum 2005;52:262-8.
41. Omdal R, Wildhagen K, Hansen T, Gunnarsson R, Kristoffersen G. Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response. Scand J Rheumatol 2005;34:229-32.
42. Brogan RJ, Eleftheriou D, Gnanapragasam J, Klein NJ, Brogan PA. Infliximab for the treatment of intravenous immunoglobulin resistant Kawasaki disease complicated by coronary artery aneurysms: a case report. Pediatr Rheumatol Online J 2009;7:3.
43. Feinstein J, Arroyo R. Successful treatment of childhood onset refractory polyarteritis nodosa with tumor necrosis factor alpha blockade. J Clin Rheumatol 2005;11: 219-22.